Marker Therapeutics, Inc.

Category: Media Coverage

Note: When you click on media articles below a new page will open indicating that you are leaving the Marker Therapeutics Website and entering a third-party web site not affiliated with Marker Therapeutics Or any of its affiliates. No information contained in a linked site has been endorsed or approved by Marker Therapeutics And Marker Therapeutics Is not responsible for the content of such third-party website.

TapImmune Enrols Last Subject in Phase II Breast Cancer Trial

US-based immuno-oncology firm TapImmune has completed patient enrolment in a Phase II clinical trial of its vaccine candidate TPIV200 to treat triple-negative breast cancer (TNBC).
Read More

Jax Company Starts Trial on Cancer-Fighting Therapy

TapImmune has enrolled its final patient in a randomized, Phase 2 clinical study of an immunotherapy that targets breast cancer.
Read More

TapImmune’s New CEO Shares the Potential of Cancer Immunotherapies

Peter Hoang loves being on the cutting-edge, and he believes Jacksonville-based TapImmune, Inc., which named him president and CEO Sept. 25, is there.
Read More

TapImmune Inc (NASDAQ:TPIV) Has Some Key Catalysts Coming Up

There are three trials that are really going to drive value for this company over the coming 24 months.
Read More

TapImmune (TPIV) Brings on Former Bellicum (BLCM) Exec as New CEO

TapImmune Inc. has a new chief executive officer. Peter Hoang, the former head of business development and strategy at Bellicum Pharmaceuticals, will take over for CEO Glynn Wilson, who has been reappointed to the position of chairman of the board of directors.
Read More

TapImmune’s (TPIV) CEO Glynn Wilson on Q2 2017 Results – Earnings Call Transcript

Second Quarterly Call Earnings Call Transcript
Read More

Trial of Vaccine to Prevent Ovarian Cancer Recurrence Expands to Advanced-Stage Patients

TapImmune has amended the criteria for patient enrollment in a Phase 2 clinical trial testing its T-cell vaccine, TPIV 200, in women with ovarian cancer.
Read More

New Options in Cancer Care

A Florida-based biotechnology company has received fast-track designation from the Food and Drug Administration to develop immunotherapy treatments for ovarian and breast cancers.
Read More

Q&A with Director of CMC Operations at TapImmune Inc. (TPIV), Robin McCallum

Robin McCallum manages all aspects of CMC Operations for TapImmune’s cancer vaccine programs.
Read More

T-Cell Vaccine Maker TapImmune Looks To Monetize Expression Tech

TapImmune says it is exploring licensing out its nucleic acid-based protein expression technology PolyStart to vaccine developers.
Read More